CINGAL faces regulatory hurdles in the U.S., but Anika is actively engaging with the FDA for approval. The commercial channel is projected to represent half of the business by 2026, supported by ...

Anika maintains a strong financial position with no debt and is executing a share buyback program. CINGAL faces regulatory hurdles in the U.S., but Anika is actively engaging with the FDA for approval ...